

SUPPLEMENTARY MATERIALS

for

Identification of small molecule inhibitors of Tau aggregation by targeting monomeric Tau as a potential therapeutic approach for Tauopathies

Marcus Pickhardt¹, Thomas Neumann², Daniel Schwizer², Kari Callaway³, Michele Vendruscolo⁴, Dale Schenk^{3,5}, Peter St. George-Hyslop^{6,7}, Eva M. Mandelkow^{1,8,9}, Christopher M. Dobson¹⁰, Lisa McConlogue^{3,11}, Eckhard Mandelkow^{*1,8,9}, Gergely Tóth^{*10,11}

¹*Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Ludwig-Erhard-Allee 2, 53175 Bonn, Germany*

²*Graffinity Pharmaceuticals, now NovAliX GmbH, Im Neuenheimer Feld 518, 69120 Heidelberg, Germany*

³*Elan Pharmaceuticals, 700 Gateway Boulevard, South San Francisco, CA 94080, USA*

⁴*Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK*

⁵*Prothena Biosciences, South San Francisco, CA, USA*

⁶*Department of Clinical Neurosciences, University of Cambridge, Cambridge Institute for Medical Research, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 0XY, United Kingdom*

⁷*Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, 6th Floor Krembil Discovery Tower, 60 Leonard Avenue, 6th Floor, 6KD417, Toronto, Ontario, M5T 2S8.*

⁸*Max Planck Institute for Neurological Research, Hamburg Outstation, c/o Deutsches Elektronen Synchrotron, Hamburg, Germany*

⁹*CAESAR Research Center/MPG, Ludwig-Erhard-Allee 2, 53175 Bonn, Germany*

¹⁰*Department of Clinical Neurosciences, Wolfson Brain Imaging Center, University of Cambridge, Addenbrooke's Hospital, Cambridge, CB2 0QQ, United Kingdom*

¹¹*MTA-TTK-NAP B - Drug Discovery Research Group – Neurodegenerative Diseases, Institute of Organic Chemistry, Research Center for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary*

*Corresponding authors:

Gergely Tóth at gt293@cam.ac.uk, and Eckhard Mandelkow at mand@mpasmb.desy.de

Figure S1:




Figure S2A-C:






Figure S3A-D:

